Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial
-
Published:2024-05
Issue:
Volume:46
Page:100771
-
ISSN:2405-6308
-
Container-title:Clinical and Translational Radiation Oncology
-
language:en
-
Short-container-title:Clinical and Translational Radiation Oncology
Author:
Fink C.A.ORCID, Ristau J.ORCID, Buchele C., Klüter S.ORCID, Liermann J.ORCID, Hoegen-Saßmannshausen P., Sandrini E., Lentz-Hommertgen A., Baumann L.ORCID, Andratschke N., Baumgartl M., Li M.ORCID, Reiner M., Corradini S., Hörner-Rieber J., Bonekamp D., Schlemmer H.-P., Belka C.ORCID, Guckenberger M., Debus J., Koerber S.A.
Reference20 articles.
1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019 2. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial;Tree;Lancet Oncol,2022 3. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial;Kishan;JAMA Oncol,2023 4. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study;Arrayeh;Int J Radiat Oncol Biol Phys,2012 5. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy;Pickett;Int J Radiat Oncol Biol Phys,1999
|
|